Study on breast cancer medication with a mobile app
Treatments studied
Part of Cancer, Skin clinical trials.
This study compares how well breast cancer patients take their medication (ribociclib) with or without using a mobile app. It aims to see if the app helps patients stick to their treatment plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stage II or III breast cancer that is hormone receptor positive and HER2 negative.
- You are at least 18 years old and have already started taking ribociclib with an aromatase inhibitor (and possibly a GnRH agonist if you are premenopausal).
- You started taking ribociclib within the past 28 days or will start soon.
- You are not currently participating in another clinical trial that involves an experimental treatment.
- You are not receiving active treatment for any other type of cancer besides breast cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how well patients take ribociclib (a cancer-fighting drug) combined with hormone therapy for early-stage breast cancer, and monitors for any side effects. The goal is to understand real-world use and help patients stay on treatment safely.
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
This study looks at how well ribociclib works when given with hormone therapy after surgery for certain types of breast cancer. It aims to understand real-world benefits and safety for patients in Russia.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This study looks at how women and men with stage II or III HR+ HER2- breast cancer do when they start treatment with ribociclib or abemaciclib (combined with hormone therapy) after surgery. Researchers want to understand real-world experiences and results.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.